E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Lymphome T refractaire ou en rechute |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025632 |
E.1.2 | Term | Malignant lymphoma |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Determine the overall response rate (ORR) (CR+CRu+PR) in relapsed T cell lymphoma. |
|
E.2.2 | Secondary objectives of the trial |
Evaluation of the tolerance and Safety of bensamustine in this subset of patients. Determination of the progression free survival (PFS), time to treatment failure (TTF), time to progression (TTP), overall survival (OS) and the duration of response.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients aged more than 18 years • Must have measurable disease on cross sectional imaging by CT that is at least 2 cm in the longest diameter and measurable in two perpendicular dimensions • Refractory or relapsed peripheral T-cell NHL (PTCL). o Peripheral T-cell lymphoma unspecified. o Angioimmunoblastic lymphadenopathy disease. o Anaplastic T-cell lymphoma (ALK positive or negative). o NK/T cell lymphoma. o Subcutaneous panniculitis T-cell lymphoma. o Hepatosplenic T-cell lymphoma. o Enteropathy associated T-cell lymphoma. • Cutaneous T cell lymphoma (CTCL) in relapse or refractory to topical therapy. o Mycosis fungoides more or equal to IIB (appendices 9) • Life expectancy > 3 months. • ECOG score 2. • No major organ dysfunction unrelated to lymphoma. Creatinine clearance > 10 ml/min. • Platelet count > 100x109/L; ANC > 1x109/L. • Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed. • Patient should be able and willing to comply with study visits and procedures per protocol.
|
|
E.4 | Principal exclusion criteria |
Pregnant or breast feeding women. • ECOG score > 2. • Estimate survival time < 3 months. •Active infection or severe organ dysfunction or psychiatric condition that unable patients to receive chemotherapy. • Creatinine clearance < 10 ml/min or severe hepatic dysfunction not related to lymphoma. • Platelet count <100x109/L; ANC < 1x109/L and not secondary to lymphoma. • Patients who receive other concurrent investigational agent. • Previous chemotherapy/immunotherapy within 3 weeks before study entry or failure to recover from associated adverse events. • Investigational treatment within 28 days before inclusion ° Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). ° Patients who are seropositive because of hepatitis B virus vaccine are eligible. Prior history of malignancies, other than T cell lymphoma, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following: − Basal cell carcinoma of the skin − Squamous cell carcinoma of the skin − Carcinoma in situ of the cervix − Carcinoma in situ of the breast − Incidental histological finding of prostate cancer (TNM stage of T1a or T1b) ° Any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study • CNS lymphoma • T-cell Leukemia lymphoma associated with HTLV1. • Sezary syndrome.
|
|
E.5 End points |
E.5.1 | Primary end point(s) | |
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |